查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030年全球抗毒液素市場
市場調查報告書
商品編碼
1311878

2023-2030年全球抗毒液素市場

Global Anti-Venom Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 133 Pages | 商品交期: 2-3個工作天內

價格

在預測期內（2023-2030年），全球抗毒液素市場預計將以7.0%的年複合成長率成長。抗毒液素通常稱為抗毒液血清，是一種用於治療被毒蛇、蜘蛛、蝎子等動物以及水母或芋螺等一些海洋物種咬傷或蟄傷症狀的藥物。擴大全球市場的主要因素包括毒液提取方法的改進、蛇毒的治療潛力以及人們對天然產品的渴望。據世界衛生組織（WHO）統計，每年約有540 萬起蛇咬傷事件，導致180 萬至270 萬起中毒事件（蛇咬傷中毒）。因此，市場參與者意識到了這一需求，並透過生產和銷售抗蛇毒產品來滿足這一需求。例如，2022年8月，印度科學研究院（IISc）班加羅爾分院的"毒液進化實驗室"與巴拉特血清和疫苗有限公司（BSV）合作，開發了地區性抗蛇毒產品。 (BSV) 合作，在印度研製針對特定地區的蛇咬傷抗毒液素。

細分市場前景

全球抗毒液素市場根據物種、抗毒液素類型、作用方式和最終用戶進行細分。根據種類，市場細分為蛇、蝎子、蜘蛛和其他。根據抗毒液素類型，市場細分為多價抗毒液素和單價抗毒液素。此外，根據作用方式，市場還可細分為細胞毒性、神經毒性、血液毒性、心臟毒性、肌毒性等。在終端用戶中，市場細分為醫院、診所和非住院手術中心。

預計多價抗毒液素細分市場將在全球抗毒液素市場中佔據相當大的佔有率

蛇咬傷事件的增加、人們對蛇咬傷認知的提高以及產品供應的改善共同推動了多價抗毒液素市場的快速成長。在預測期內，預計多價抗毒液素將佔據相當大的市場佔有率。多價抗毒液素由抗體組成，可中和來自不同物種和屬的多種同源毒液。多價蛇類抗毒液素的有效成分包括大班蛇抗毒液素、死亡加藤蛇抗毒液素、褐蛇抗毒液素和虎蛇毒血清。即使在毒蛇種類不明、無法選擇單價抗毒液素的情況下，多價抗毒液素也能挽救受害者的生命。多價抗毒液素因其明顯的優勢而成為最常用的抗毒液素藥物。

區域展望

全球抗毒液素市場根據地域進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國、日本、韓國和亞洲其他地區）和世界其他地區（中東和非洲以及拉丁美洲）。其中，由於CroFab、Smithsonian、Rare Disease Therapeutics Inc.等市場解決方案供應商高度集中，預計亞太地區將在全球市場中佔據顯著佔有率。

北美有望在全球抗蛇毒市場中保持顯著的年複合成長率

由於該地區毒蛇咬傷和其他危險咬傷的發生率較高，公眾對毒蛇咬傷的認知不斷提高，技術不斷改進，這些都是預計該市場將佔據相當大佔有率的一些主要因素。在北美，美國預計將對市場擴張產生相當大的影響。根據美國疾病控制和預防中心（CDC）2021年6月發表的一篇文章，美國每年約有7000-8000 人被毒蛇咬傷。僱員被毒蛇咬傷後非但不會死亡，反而更有可能受到長期傷害。由於蛇咬傷在美國非常普遍，預計市場將因對其療法需求的增加而上升。此外，重要的關鍵市場參與者的產品批准和戰略計劃預計也將推動該國市場的擴張。例如，2022年3月，Ophirex 公司宣布美國食品和藥物管理局已將varespladib-methyl（"口服varespladib"）指定為治療蛇咬傷的快速通道藥物。

市場參與者展望

服務於抗毒液素市場的主要公司包括Bharat Serums and Vaccines Ltd. (BSV), Boehringer Ingelheim International GmbH, Pfizer Inc., MicroPharm Ltd., Merck & Co. Inc., and BTG International Inc., Rare Disease Therapeutics Inc.等。為了保持市場競爭力，市場參與者採取了各種策略，包括併購、建立夥伴關係、合作、融資和推出新產品等，大大促進了市場的成長。例如，2022年8月，總部位於印度的生物製藥機構Bharat Serums and Vaccines（BSV）與印度班加羅爾科學研究所（IISc）的"進化基因組學實驗室"建立了戰略合作夥伴關係，共同研製針對特定地區的抗毒液素，為該國下一代蛇咬傷治療方法的開發鋪平了道路。

報告內容包括

  • 2022年的市場價值資料分析以及到2030年的預測。
  • 各細分市場的年化市場收入（百萬美元）。
  • 主要地區的國別分析。
  • 全球抗毒液素市場的主要營運公司。根據資料的可用性，報告還提供了與新產品發布和相關新聞有關的資訊。
  • 透過確定未來強勁成長的關鍵細分市場，分析商業戰略。
  • 市場進入和市場擴張戰略分析。
  • 透過確定市場中的"地位"來製定競爭戰略。

目 錄

第1章：報告摘要

  • 行業現狀分析與成長潛力展望
  • 研究方法和工具
  • 市場細分
    • 按細分市場
    • 按地區

第2章：市場概述與洞察

  • 報告範圍
  • 分析師洞察與當前市場趨勢
    • 主要結論
    • 建議
    • 結論

第3章：競爭格局

  • 主要公司分析
  • Bharat Serums and Vaccines Ltd. (BSV)
    • 概述
    • 財務分析
    • SWOT 分析
    • 近期發展
  • Boehringer Ingelheim International GmbH
    • 公司概況
    • 財務分析
    • SWOT 分析
    • 近期發展
  • Boston Scientific Corp.
    • 概述
    • 財務分析
    • SWOT 分析
    • 近期發展
  • 關鍵戰略分析

第4章：市場細分

  • 按物種分類的全球抗毒液素市場
    • 蛇類
    • 蝎子
    • 蜘蛛
    • 其他（海洋動物、昆蟲）
  • 按抗毒液素類型分類的全球抗毒液素市場
    • 多價抗毒液素
    • 單價抗毒液素
  • 按作用方式分類的全球抗毒液素市場
    • 細胞毒性
    • 神經毒性
    • 血液毒性
    • 心臟毒性
    • 肌毒性
    • 其他（磷脂酶A2 (PLA2s)、出血性金屬蛋白酶）
  • 按最終用戶分類的全球抗血清市場
    • 醫院
    • 診所
    • 門診手術中心

第5章: 區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第6章：公司簡介

  • Bioclon Institute
  • BTG International Inc.
  • CSL Ltd.
  • Flynn Pharma
  • Haffkine Bio-Pharmaceutical Corp Ltd.
  • Incepta Pharmaceuticals Ltd.
  • Inosan Biopharma
  • Instituto Vital Brazil
  • MicroPharm Ltd.
  • Merck & Co. Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Rare Disease Therapeutics Inc.
  • Sigma-Aldrich Co.
  • VINS Bio Products Ltd.
Product Code: OMR2027477

Title: Global Anti-venom Market Size, Share & Trends Analysis Report by Species (Snake, Scorpion, Spider, and Others), by Anti-Venom Type (Polyvalent Anti-venom and Monovalent Anti-venom), by Mode of Action (Cytotoxic, Neurotoxic, Hemotoxic, Cardiotoxic, Myotoxic, and Others), by End-User (Hospitals, Clinics and Ambulatory Surgical Centers), Forecast Period (2023-2030).

The global anti-venom market is anticipated to grow at a CAGR of 7.0% during the forecast period (2023-2030). Anti-venom, often referred to as venom antiserum, is a type of drug used to treat the symptoms of venomous bites or stings from animals, such as snakes, spiders, scorpions, and some marine species such as jellyfish or cone snails. The major factor expanding the market globally include improvements in venom extraction methods, the therapeutic potential of snake venom, and the desire for natural products. According to the World Health Organization (WHO), every year roughly 5.4 million snake bites, resulting in 1.8 to 2.7 million instances of envenoming's (snake bite poisoning). Hence, the market participants are aware of this demand and are working to satisfy it by creating and distributing anti-venom products. For Instance, in August 2022, The Indian Institute of Science (IISc) Bangalore's 'Evolutionary Venomics Lab' and Bharat Serums and Vaccines Ltd. (BSV) partnered to create region-specific antivenom for snakebites in India.

Segmental Outlook

The global anti-venom market is segmented based on species, anti-venom type, mode of action, and end user. Based on the species, the market is sub-segmented into snake, scorpion, spider, and others. Based on anti-venom type, the market is sub-segmented into polyvalent anti-venom and monovalent anti-venom. Further, on the basis of the mode of action, the market is sub-segmented into cytotoxic, neurotoxic, haemotoxic, cardiotoxic, myotoxic, and others. Among the end user, the market is sub-segmented into hospitals, clinics, and ambulatory surgical centers.

The Polyvalent Anti-venom Sub-Segment is Anticipated to Hold a Considerable Share of the Global Anti-venom Market

The combination of increased snakebite incidents, growing awareness, and improved product offerings has driven the fast growth of the polyvalent antivenom market. Over the course of the forecast period, a sizable market share is anticipated for the polyvalent anti-venoms segment. Polyvalent anti-venoms are made up of antibodies that may neutralize a number of homologous venoms from various species and genera. The active components of polyvalent snake antivenom include taipan antivenom, death adder antivenom, brown snake antivenom, and tiger snake antivenom. Even when the snake responsible for the envenomation is unknown and a monovalent antivenom cannot be selected, polyvalent antivenoms can save the lives of victims. Polyvalent anti-venoms are the most used anti-venom medication due to their evident benefits.

Regional Outlook

The global anti-venom market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the high concentration of the market solution vendors including CroFab, Smithsonian, Rare Disease Therapeutics Inc., and others.

North America is Expected to Hold a Significant CAGR in the Global Anti-Venom Market

Due to the high rate of snakebites and other dangerous bites in the area, the growing public awareness of venomous bites, and growing technological improvements are some of the major factors anticipated to hold a considerable share of the market. In North America, the US is anticipated to have a sizable impact on market expansion. According to a Centers for Disease Control and Prevention (CDC) article published in June 2021, in US around 7,000-8,000 individuals were bitten by venomous snakes every year. Rather than dying from snake bites, employees are much more likely to sustain long-term injuries. Due to snake bites being so common there, the market is anticipated to rise as a result of the rising demand for its therapies. Moreover, Product approvals and strategic moves by important key market players are also anticipated to boost market expansion in the nation. For instance, in March 2022, Ophirex, Inc. declared that the US FDA had given varespladib-methyl ("oral varespladib") Fast Track designation for the treatment of snakebite.

Market Players Outlook

The major companies serving the anti-venom market include: Bharat Serums and Vaccines Ltd. (BSV), Boehringer Ingelheim International GmbH, Pfizer Inc., MicroPharm Ltd., Merck & Co. Inc., and BTG International Inc., Rare Disease Therapeutics Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in August 2022, Bharat Serums and Vaccines (BSV), an India-based biopharmaceutical organization strategically partnered with the "Evolutionary Genomics Lab" at the Indian Institute of Science (IISc) Bangalore to create region-specific antivenoms and pave the way for the country's next-generation snakebite treatment.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global anti-venom market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Bharat Serums and Vaccines Ltd. (BSV)
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Boehringer Ingelheim International GmbH
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Boston Scientific Corp.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Anti-Venom Market by Species
    • 4.1.1. Snake
    • 4.1.2. Scorpion
    • 4.1.3. Spider
    • 4.1.4. Others (Marine animals, Insects)
  • 4.2. Global Anti-Venom Market by Anti-venom Type
    • 4.2.1. Polyvalent Anti-venom
    • 4.2.2. Monovalent Anti-venom
  • 4.3. Global Anti-Venom Market by Mode of Action
    • 4.3.1. Cytotoxic
    • 4.3.2. Neurotoxic
    • 4.3.3. Haemotoxic
    • 4.3.4. Cardiotoxic
    • 4.3.5. Myotoxic
    • 4.3.6. Others (Phospholipase A2 (PLA2s), hemorrhagic metalloproteinases)
  • 4.4. Global Anti-Venom Market by End User
    • 4.4.1. Hospitals
    • 4.4.2. Clinics
    • 4.4.3. Ambulatory Surgical Centers

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Bioclon Institute
  • 6.2. BTG International Inc.
  • 6.3. CSL Ltd.
  • 6.4. Flynn Pharma
  • 6.5. Haffkine Bio-Pharmaceutical Corp Ltd.
  • 6.6. Incepta Pharmaceuticals Ltd.
  • 6.7. Inosan Biopharma
  • 6.8. Instituto Vital Brazil
  • 6.9. MicroPharm Ltd.
  • 6.10. Merck & Co. Inc.
  • 6.11. Merck KGaA
  • 6.12. Pfizer Inc.
  • 6.13. Rare Disease Therapeutics Inc.
  • 6.14. Sigma-Aldrich Co.
  • 6.15. VINS Bio Products Ltd.

LIST OF TABLES

  • 1. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY SPECIES, 2022-2030 ($ MILLION)2022-2030 ($ MILLION)
  • 2. GLOBAL SNAKE ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL SCORPION ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL SPIDER ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL OTHERS ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY ANTI-VENOM TYPE, 2022-2030 ($ MILLION)
  • 7. GLOBAL POLYVALENT ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL MONOVALENT ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 10. GLOBAL CYTOTOXIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 11. GLOBAL NEUROTOXIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 12. GLOBAL HAEMOTOXIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 13. GLOBAL CARDIOTOXIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 14. GLOBAL OTHERS ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 15. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 16. GLOBAL ANTI-VENOM IN HOSPITALS MARKET RESEARCH AND ANALYSIS 2022-2030 ($ MILLION)
  • 17. GLOBAL ANTI-VENOM IN CLINICS MARKET RESEARCH AND ANALYSIS 2022-2030 ($ MILLION)
  • 18. GLOBAL ANTI-VENOM IN AMBULATORY SURGICAL CENTERS MARKET RESEARCH AND ANALYSIS 2022-2030 ($ MILLION)
  • 19. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY SPECIES, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY VENOM TYPE, 2022-2030 ($ MILLION)
  • 23. NORTH AMERICAN ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 24. NORTH AMERICAN ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 25. EUROPE ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY SPECIES, 2022-2030 ($ MILLION)
  • 26. EUROPE ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY VENOM TYPE, 2022-2030 ($ MILLION)
  • 27. EUROPE ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 28. EUROPE ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 29. ASIA-PACIFIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY SPECIES, 2022-2030 ($ MILLION)
  • 30. ASIA-PACIFIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY VENOM TYPE, 2022-2030 ($ MILLION)
  • 31. ASIA-PACIFIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 32. ASIA-PACIFIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY SPECIES, 2022-2030 ($ MILLION)
  • 34. REST OF THE WORLD ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY VENOM TYPE, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 36. REST OF THE WORLD ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ANTI-VENOM MARKET SHARE BY SPECIES, 2022 VS 2030 (%)
  • 2. GLOBAL SNAKE ANTI-VENOM MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL SCORPION ANTI-VENOM MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL SPIDER ANTI-VENOM MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL OTHERS ANTI-VENOM MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY ANTI-VENOM TYPE, 2022 VS 2030 (%)
  • 7. GLOBAL POLYVALENT ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL MONOVALENT ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022 VS 2030 (%)
  • 10. GLOBAL CYTOTOXIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022 VS 2030 (%)
  • 11. GLOBAL NEUROTOXIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022 VS 2030 (%)
  • 12. GLOBAL HAEMOTOXIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022 VS 2030 (%)
  • 13. GLOBAL CARDIOTOXIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022 VS 2030 (%)
  • 14. GLOBAL OTHERS ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022 VS 2030 (%)
  • 15. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY END USER, 2022 VS 2030 (%)
  • 16. GLOBAL ANTI-VENOM IN HOSPITALS MARKET RESEARCH AND ANALYSIS, 2022 VS 2030 (%)
  • 17. GLOBAL ANTI-VENOM IN CLINICS MARKET RESEARCH AND ANALYSIS, 2022 VS 2030 (%)
  • 18. GLOBAL ANTI-VENOM IN AMBULATORY SURGICAL CENTERS MARKET RESEARCH AND ANALYSIS, 2022 VS 2030 (%)
  • 19. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 20. US ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. CANADA ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. UK ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. FRANCE ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. GERMANY ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. ITALY ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SPAIN ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF EUROPE ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. INDIA ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. CHINA ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. JAPAN ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. SOUTH KOREA ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 32. REST OF ASIA-PACIFIC ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)